Glyciphage SR

Drug Class

Available Strengths

Mechanism of Action

1. Reduces hepatic gluconeogenesis — primary and most significant action; inhibits mitochondrial complex I in the liver
2. Increases peripheral insulin-mediated glucose uptake — improves insulin sensitivity in skeletal muscle
3. Slows intestinal glucose absorption
4. Activates AMP-activated protein kinase (AMPK), which mediates many of its downstream effects

Indications

• Type 2 Diabetes Mellitus — first-line agent (per ADA, WHO, and most guidelines)
• Polycystic Ovary Syndrome (PCOS) — insulin sensitization
• Pre-diabetes / impaired glucose tolerance — prevention of progression
• Metabolic syndrome

Advantage of SR (Sustained Release) over IR (Immediate Release)

Dosing

• Always taken with or after meals to further reduce GI upset
• SR tablets should be swallowed whole — do not crush or chew

Renal Dosing (eGFR-based)

Side Effects

• Common: Nausea, diarrhea, metallic taste, abdominal discomfort (especially initially; much less with SR formulation)
• Serious (rare): Lactic acidosis — incidence ~2–5 per 100,000 patient-years; risk increases with renal impairment, hepatic failure, hypoxia, dehydration (Diabetes Management in Wilderness Athletes, p. 10)
• Long-term use: Vitamin B12 deficiency (monitor annually)

Contraindications

• eGFR < 30 mL/min/1.73 m² (significant renal impairment)
• Hepatic failure
• Active or metabolic acidosis
• Conditions predisposing to hypoxia (severe heart failure, respiratory failure, sepsis)
• Iodinated contrast media procedures — hold 48 hours before and after

Drug Interactions

• Alcohol — increased lactic acidosis risk
• Iodinated contrast — hold before procedures
• Carbonic anhydrase inhibitors (e.g., acetazolamide, topiramate) — may increase lactic acidosis risk
• Cimetidine — increases metformin levels (reduces renal tubular secretion)

Key Benefits

• Weight neutral to modest weight loss
• No hypoglycemia as monotherapy
• Cardiovascular benefit (UKPDS data)
• Low cost
• Extensive safety record over decades

Doxofylline 400 mg

Drug Class

Available Formulations

Mechanism of Action

1. Phosphodiesterase (PDE) inhibition — inhibits PDE3 and PDE4, preventing breakdown of intracellular cAMP → smooth muscle relaxation → bronchodilation
2. Adenosine receptor antagonism — blocks bronchoconstricting adenosine receptors in the airways
3. Anti-inflammatory effects — reduces airway inflammation via cAMP-mediated pathways
4. Mucociliary clearance — improves ciliary beat frequency

Key distinction from theophylline: Doxofylline has minimal or no affinity for adenosine A1 receptors in the heart and CNS, which is why it lacks the cardiovascular (tachycardia, arrhythmia) and CNS (seizures, insomnia) side effects associated with theophylline.

Indications

• Bronchial asthma — chronic management and acute exacerbations
• COPD (Chronic Obstructive Pulmonary Disease) — bronchospasm relief
• Chronic bronchitis with bronchospasm
• Emphysema

Dosing

• Taken after meals to reduce GI irritation
• Tablets should be swallowed whole
• No therapeutic drug monitoring required (unlike theophylline) due to wider therapeutic index

Comparison: Doxofylline vs Theophylline

Side Effects

• Nausea, epigastric discomfort
• Headache
• Palpitations (rare at therapeutic doses)
• Dizziness

• Tachycardia / arrhythmia (much less than theophylline)
• Seizures (very rare)
• Hypotension

Contraindications

• Hypersensitivity to xanthines
• Active peptic ulcer disease (relative contraindication)
• Recent myocardial infarction with arrhythmias
• Severe hepatic impairment (use with caution; reduce dose)

Drug Interactions

• Erythromycin, ciprofloxacin — increase doxofylline plasma levels (CYP inhibition)
• Rifampicin, phenytoin — reduce plasma levels (CYP induction)
• Beta-blockers — may antagonize bronchodilator effect
• Lithium — xanthines may reduce lithium levels
• Sympathomimetics — additive cardiovascular effects (use cautiously)

Pregnancy & Lactation

• Pregnancy: Category C — use only if benefit outweighs risk; crosses placenta
• Lactation: Excreted in breast milk; caution advised

Clinical Positioning

• Add-on therapy when inhaled bronchodilators (SABA, LABA) and ICS provide inadequate control
• Alternative to theophylline in patients who cannot tolerate theophylline's side effects
• Particularly useful in resource-limited settings where inhalers have compliance issues, as it is an oral tablet with good efficacy and tolerability

• Is the patient using this drug off-label for sleep, or is insomnia a side effect of stopping it?
• What is the patient's underlying condition?

Important Note: Post-Angiography Consideration

Alternatives to Doxofylline for This Patient

1. ICS + LABA Combination Inhaler (First-line preferred)

• Controls both inflammation and bronchospasm
• Formoterol has rapid onset — especially useful for nocturnal symptoms
• ICS reduces asthma mortality and is safe in cardiac patients
• Once or twice daily — excellent compliance

2. LAMA (Long-Acting Muscarinic Antagonist)

• Safe in cardiac patients
• Reduces nocturnal symptoms effectively

3. Montelukast (Leukotriene Receptor Antagonist)

• Anti-inflammatory, bronchodilator-sparing
• Excellent safety profile — safe post-angiography
• Especially useful if allergic component is present

4. SABA (Short-Acting Beta-2 Agonist) — Rescue use

• For breakthrough nocturnal symptoms, not maintenance
• Safe in cardiac patients at standard inhaled doses

Recommended Approach for This Patient

Step 1: Start ICS + LABA combination inhaler (e.g., Budesonide + Formoterol)
         → Controls nocturnal inflammation and bronchospasm

Step 2: Add Montelukast 10 mg at night
         → Addresses nocturnal and allergic component

Step 3: Keep SABA inhaler (Salbutamol) as rescue

Step 4: If still uncontrolled → Add Tiotropium (LAMA)

Step 5: Doxofylline can be gradually tapered once above control is achieved

Why Inhalers Are Better Than Oral Doxofylline Here

• Targeted delivery to airways — lower systemic dose
• Safer cardiac profile — important given the angiography history
• Less drug interactions
• Doxofylline, while better than theophylline, still has mild cardiac effects that are undesirable in a patient with known coronary artery disease

Key clinical point: If the patient is on a cardioselective beta-blocker (e.g., metoprolol, bisoprolol) post-angiography, it should generally be continued even in asthmatics if cardiac indication is strong — but monitor closely for bronchospasm. Avoid non-selective beta-blockers entirely.